Siren Biotechnology and Catalent Inc. entered a strategic partnership to support the development and manufacturing of Siren Biotechnology's AAV immuno-gene therapies. Under the partnership, Catalent will provide process development and cGMP manufacturing of Siren Biotechnology's adeno-associated viral (AAV) vector-based therapeutic candidates for use in clinical trials. Catalent will further support process optimization at its process and clinical development center in Baltimore, MD.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
53.79 USD | +0.34% | -1.88% | +19.72% |
May. 29 | Catalent Shareholders Approve Deal With Novo Holdings | MT |
May. 29 | Catalent stockholders approve deal with Novo Holdings | RE |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+19.72% | 9.7B | |
+40.73% | 734B | |
+32.83% | 591B | |
-6.30% | 350B | |
+15.15% | 315B | |
+4.05% | 276B | |
+15.00% | 238B | |
+9.78% | 206B | |
-5.52% | 204B | |
+6.17% | 161B |
- Stock Market
- Equities
- CTLT Stock
- News Catalent, Inc.
- Siren Biotechnology and Catalent Enter Partnership for Manufacturing of AAV Gene Therapies for Cancer